Paul Duncan, 47 years old, joined The Binding Site in 1992 where he held a variety of sales and marketing positions both domestically and internationally until he was appointed to The Binding Site Board as Sales and Marketing Director in September 2006. He joined The Binding Site from Ortho Diagnostic Systems, the lab diagnostics company within the Johnson & Johnson group.
During his career at Ortho Diagnostic Systems, Paul was responsible for sales of blood grouping and flow cytometry equipment and reagents across Wales and the West of England. He was appointed as National Sales Specialist for Instruments and later to National Blood Screening Manager, where he was responsible for the introduction of hepatitis C tests into the National Blood Transfusion Service. Paul has a technical background in Haematology and Immunohaematology. He is a Fellow of the Institute of Biomedical Sciences and practised as a Senior Scientific Officer in the Royal Gwent Hospital, Newport.
As part of the Board changes, Anne Grainger has been appointed to the Board as International Sales Director in addition to her current role as Vice President Sales and Technical Service based in The Binding Site in the U.S.. Anne has been with the Company since 1986 when The Binding Site Inc. was founded in San Diego. With a track record of devising and implementing successful sales strategies in the U.S., Anne brings a wealth of experience to the U.K. Board that will enhance her role across the worldwide markets.
Commenting on today’s announcement, Professor Jo Bradwell, Executive Chairman of The Binding Site, said:
“I am delighted to announce the promotion of Paul Duncan to Chief Executive Officer. His knowledge and experience, coupled with his extensive sales and marketing expertise, has made a significant contribution to The Binding Site and will continue to benefit the Company in its future growth. I would also like to take this opportunity to welcome Anne Grainger to the Board. Anne’s international role will be extremely important as we continue to grow our business worldwide.”
Paul Duncan, Chief Executive Officer of The Binding Site, said:
“The Binding Site is a very successful and interesting company which is already delivering enormous benefits to patients across the world. The past sixteen years have been highly rewarding and I am very much looking forward to the new challenge as CEO.”
